Le Lézard
Classified in: Health, Business
Subject: TNM

BayMark Health Services Acquires Los Angeles Area Opioid Treatment Program


SUN VALLEY, Calif., June 20, 2020 /PRNewswire-PRWeb/ -- BayMark Health Services announced the acquisition of Narcotic Addiction Treatment Agency (NATA), an Opioid Treatment Program (OTP) in Sun Valley, CA. Providing medication-assisted treatment (MAT) in the San Fernando Valley for more than 35 years, NATA has established themselves as a key provider of comprehensive treatment for opioid addiction in a professional and compassionate environment. The NATA program will join six established BayMark-owned programs in the Greater Los Angeles area.

NATA provides outpatient methadone maintenance and detoxification combined with substance use counseling and behavioral therapies. This evidence-based approach is individualized to meet the needs of each patient. Additional services include addiction and relapse education, coordinated treatment during pregnancy, in-house lab services and referrals to community resources to assist patients in rebuilding their lives.

David K. White, Ph.D., Chief Executive Officer of BayMark Health Services, said, "While California is a leader in affordable, accessible opioid use disorder (OUD) treatment, there is still a need to expand and enhance those services in response to the unabating opioid crisis. BayMark has a significant presence in the State and is pleased to continue growing that footprint to provide services to Californians in need of help."

Medication-assisted treatment reduces the symptoms of opioid withdrawal and cravings, paving the way for patients to focus on addressing the underlying causes of their addiction and supporting them to regain stability in their lives. Opioid treatment programs offer a proven alternative to residential or abstinence-based treatment models for OUDs.

For more information on BayMark Health Services, visit: http://www.BayMark.com.

About BayMark Health Services:
BayMark Health Services provides medication-assisted treatment to 53,000+ patients in recovery from substance use disorder across the United States and Canada. Our outpatient programs deliver medically-supervised treatment, in a variety of modalities and settings, to meet the diverse needs of our patients who struggle with the use of opioids, alcohol and other prescription and illicit substances.

The BayMark continuum of patient-focused services includes: highly structured opioid treatment programs utilizing methadone or buprenorphine and outpatient buprenorphine treatment programs, both of which incorporate counseling as part of an individualized treatment plan for opioid use disorder. Additionally, ambulatory withdrawal management services with naltrexone therapy, and inpatient detoxification services are offered for a variety of substance use disorders.

 

SOURCE BayMark Health Services


These press releases may also interest you

at 07:35
Ironwood Pharmaceuticals, Inc. , a GI-focused healthcare company, today announced positive, primary results up to Day 91 for its Phase II exploratory STARGAZE trial evaluating apraglutide in patients with steroid-refractory gastrointestinal acute...

at 07:35
dentalcorp Holdings Ltd. ("dentalcorp" or the "Company") , Canada's largest and one of North America's fastest growing networks of dental practices, today announced that it will present at the following investor conferences: 2024 Bloom Burton & Co....

at 07:30
Optimi Health Corp. (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances such as natural psilocybin and MDMA, proudly announces its role as a Presenting Sponsor at the highly...

at 07:30
Theratechnologies Inc. ("Theratechnologies" or the "Company") , a biopharmaceutical company focused on the development and commercialization of...

at 07:30
Quipt Home Medical Corp. (the "Company") ?, a U.S. based home medical equipment provider, focused on end-to-end respiratory care, today announced the voting results from its annual general and special meeting of shareholders held on March 27, 2024...

at 07:30
Ophthalmic lens technology leader HOYA Vision Care announced the launch of iD LifeStyle® 4 with 3D Binocular Visiontm technology, the newest progressive lens in its award-winning iD LifeStyle® family, now available to order across Canada. Building...



News published on and distributed by: